RNWL
INTERNATIONAL REGISTRATION RENEWED
18/12/2025
Voltar para busca
Dado oficial do USPTO
AFT PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
AFT PHARMACEUTICALS
ST13
US500000079183211Classe
5
Pedido
79183211
Registro
5293339
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
54
Atualização mais recente
19/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
17/12/2015
Data de registro
26/09/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/05/2024
Última transação
19/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
Takapuna Auckland, NZ
Examinador
LEIPZIG,MARC J
Unidade examinadora
M60
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited
Representantes
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of symptoms of cold and flu; pharmaceutical preparations for the treatment of inflammatory diseasesinflammatory bowel diseasesinflammatory connective tissue diseases; pharmaceutical preparations for pain relief; pharmaceutical preparationsantihistamines for relief of symptoms of allergies and allergic conditions; pharmaceutical preparations for the treatment of the musculo-skeletal systemconnective tissue diseasesbone diseasesspinal diseasesback painfracturessprainscartilage injuries; pharmaceutical preparationsnasal spray for treating symptoms of allergies and allergic conditions: pharmaceutical preparationsointment for treatment of scalp conditions and skin infections; pharmaceutical preparations for use in ocular disorders: pharmaceutical preparationsmoisturizing eye ointmenteye drops for treatment of conjunctivitis and symptoms of allergies; pharmaceutical preparationsgel for the treatment of oral conditions: pharmaceutical preparationsdietary supplements for general health and well-being ;pharmaceutical preparationslaxatives; pharmaceutical preparationslotions for the treatment of head lice; pharmaceutical preparationsanti-fungal nail lacquer; and cream for the relief of pain associated with osteoarthritis
Publicações
Histórico de despachos e eventos da marca no USPTO.
54 publicações encontradas
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
06/06/2025
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
31/03/2025
INPC
INVALIDATION PROCESSED
31/03/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
16/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/09/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
27/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/09/2024
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
16/05/2024
71AG
REGISTERED-SEC.71 ACCEPTED
16/05/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/05/2024
ES71
TEAS SECTION 71 RECEIVED
20/09/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
26/09/2022
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
03/08/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
29/07/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/02/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/01/2018
FIMP
FINAL DISPOSITION PROCESSED
13/01/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/12/2017
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
29/11/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
29/11/2017
ES7R
TEAS SECTION 7 REQUEST RECEIVED
08/10/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/10/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
26/09/2017
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/08/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/07/2017
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
26/07/2017
PUBO
PUBLISHED FOR OPPOSITION
11/07/2017
GPNX
NOTIFICATION PROCESSED BY IB
08/07/2017
FAXX
FAX RECEIVED
25/06/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/06/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
21/06/2017
NPUB
NOTICE OF PUBLICATION
21/06/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/06/2017
CNEA
EXAMINERS AMENDMENT MAILED
24/05/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/05/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
24/05/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
24/05/2017
CNFR
FINAL REFUSAL MAILED
20/10/2016
CNFR
FINAL REFUSAL WRITTEN
19/10/2016
ACEC
AMENDMENT FROM APPLICANT ENTERED
28/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/09/2016
ALIE
ASSIGNED TO LIE
22/09/2016
FAXX
FAX RECEIVED
14/09/2016
RFNT
REFUSAL PROCESSED BY IB
13/05/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/04/2016
RFRR
REFUSAL PROCESSED BY MPU
07/04/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/04/2016
CNRT
NON-FINAL ACTION WRITTEN
06/04/2016
DOCK
ASSIGNED TO EXAMINER
05/04/2016
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/02/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/02/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AFT PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.